Keyphrases
Hospital Setting
100%
Other-concern
100%
Sodium-glucose Cotransporter
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Diabetic Ketoacidosis
100%
Other-benefit
100%
Inpatient Setting
28%
Risk Factors
14%
Cardiovascular Mortality
14%
Published Data
14%
Therapy Initiation
14%
Potential Risk
14%
Systolic Blood Pressure
14%
Acute Decompensated Heart Failure
14%
Euglycemic
14%
Outpatient Therapy
14%
Antihyperglycemic
14%
Non-diabetic Population
14%
Euglycemic Diabetic Ketoacidosis
14%
EMPA-REG
14%
Medicine and Dentistry
Diabetic Ketoacidosis
100%
Sodium Glucose Cotransporter 2
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Outpatient
42%
Systolic Blood Pressure
14%
Cardiovascular System
14%
Acute Decompensated Heart Failure
14%
Antidiabetic Agent
14%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
14%
Pharmacology, Toxicology and Pharmaceutical Science
Sodium Glucose Cotransporter 2
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Diabetic Ketoacidosis
100%
Acute Heart Failure
14%
Antidiabetic Agent
14%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
14%